PATIENT ALERT: Information regarding Coronavirus (COVID-19).  

Clinical Research & Trials

USO 20225

A Phase 2, Multicenter, Single-Arm, Open-Label Study To Evaluate The Efficacy And Safety Of AK104 In Subjects With Recurrent Or Metastatic Cervical Cancer (AK104-201-AU) STAR

 

Disease Types: GYN Cancer Research

Eligibility Requirements:

-recurrent or metastatic cervical (squamous or adeno-squamous) cancer not treatable with surgery or radiation therapy
-progression during or following prior platinum doublet chemotherapy for recurrent or metastatic disease
-measurable disease
-no CNS metastasis, hydronephrosis (not treatable with nephrostomy or ureteral stents), known HIV, active Hep B or Hep C 
auto-immune disease (diabetes I, hypothyroidism, and skin conditions aren’t exclusions), lung disease or pneumonitis, prior hypersensitivity
to monoclonal antibodies, clinically significant cardio- or cerebral vascular disease, or prior stem cell or organ transplantation

Available at: